Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-positive metastatic breast cancer
NCT04829604Phase 2Active, not recruiting
- Sponsor
- Ambrx
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of anvatabart opadotin in HER2-positive metastatic breast cancer, sponsored by Ambrx. Primary endpoint: Objective Response Rate at 2 years. Started Oct 2021; status: active, not recruiting.
02
Drugs
anvatabart opadotin
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT04829604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829604.